|By Business Wire||
|May 7, 2014 10:04 AM EDT||
Please replace the release with the following corrected version due to multiple revisions.
The corrected release reads:
MOLECULARHEALTH GUIDES BETTER CANCER TREATMENTS WITH TWO NEW DIAGNOSTIC TESTS
TreatmentMAP platform combines precision medicine with advanced data analytics to guide patients and physicians to the safest, most effective cancer treatment options
Backed by more than eight years of research and development, MolecularHealth announced today the official launch of TreatmentMAP™, its cancer treatment decision support offering. Based on a proprietary analytics engine, TreatmentMAP leverages the results of next generation sequencing (NGS) genetic tests to identify the optimal, safest treatment options for each individual patient. For the first time, cancer patients and their medical teams will have access to actionable information to guide the selection of targeted cancer treatments, presented in a clear and understandable way. TreatmentMAP became commercially available in Europe and the U.S. in April.
The company has two available versions of its offering:
- TreatmentMAP Targeted Panel is the largest gene panel commercially available today, with over 500 genes that cover several thousand variants and have been determined to have the most clinical impact in cancer, and are therefore most likely to make a difference in treatment outcome.
- TreatmentMAP Whole Exome, the first commercially available whole exome analysis for cancer, taking a comprehensive look at a patient’s genetic profile by examining the genes of both the tumor and germline.
Both testing options incorporate MolecularHealth’s SafetyMAP™, a proprietary identification of drug target safety or resistance effects, using the FDA’s Adverse Event Reporting Systems (AERS) as an input for analysis. Through MolecularHealth’s five-year research collaboration agreement with the FDA, MolecularHealth incorporates key data from AERS into SafetyMAP, providing the first drug safety analysis that combines adverse event information with molecular knowledge about drug activity within a patient. This ensures that treatment options will not only be effective, but won’t have unintended negative consequences for patients.
“I believe that the future of medicine lies in our ability to interpret seemingly disparate information,” said Lloyd Everson, M.D., co-CEO of MolecularHealth. “With the technology now at our disposal, there are mountains of data constantly being churned out of labs and clinical trials – but until recently, it was an unwieldy task to do anything productive with that information. TreatmentMAP allows us to pull in all of that data and make it truly usable.”
TreatmentMAP tests can be ordered in the United States and in Europe. In the U.S., a patient’s oncologist or pathologist sends a tumor sample to MolecularHealth’s CLIA-certified NGS lab in The Woodlands, Texas. Once the sample is sequenced, data on the tumor’s DNA, along with additional medical information on the patient, is fed into the company’s automated analytics platform. This platform cross-references patient-specific data with the latest peer-reviewed evidence, clinical trials, and other sources. A simple-to-understand report is delivered to the patient’s medical team, highlighting the treatment options that are most likely to be both effective and safe.
“We are still trying to understand cancer, and as an oncologist I have observed that the most effective cancer therapies are those that precisely target the unique biology of an individual patient's tumor,” said Joyce O’Shaughnessy, M.D., co-chair of breast cancer research at US Oncology and Baylor-Sammons Cancer Center. “TreatmentMAP offers new insights into the molecular drivers of a tumor, leading to expanded therapeutic options and greater chance for therapy response.”
“As a pathologist, I’m happy to have a company joining the molecular diagnostic space that’s more pathologist-friendly than some of the competition in this field,” said Thomas Wheeler, M.D., chairman of the Department of Pathology & Immunology at Baylor College of Medicine. “The market can only benefit from having more options to meet the needs of individual patients, and from what I’ve seen, MolecularHealth’s reports are not only more robust, but focus on the elements that are most important when determining a treatment path for a patient.”
Drs. O’Shaughnessy and Wheeler are members of the MolecularHealth advisory board.
For more information on TreatmentMAP and how to order a test, please visit MolecularHealth’s website.
MolecularHealth is a leading biomedical company transforming molecular data into actionable clinical information for the most efficient and safest cancer treatment options for each individual cancer patient. By using advanced proprietary tumor analysis and interpretation to match patient-specific genetic and molecular test findings to the current state of the world’s biomedical knowledge about cancer, MolecularHealth provides doctors and patients with faster, more accurate insights into the role genes play in the progression and treatment of an individual’s cancer. Eight years in development by a multidisciplinary team of doctors, scientists and IT experts, MolecularHealth works in partnership with some of the world’s leading healthcare and information technology companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, and SAP AG. The company is headquartered in Heidelberg, Germany. U.S. headquarters, including a CLIA-certified NGS lab, are located in The Woodlands, Texas. The company also has offices in Boston, Mass.
In his session at 16th Cloud Expo, Simone Brunozzi, VP and Chief Technologist of Cloud Services at VMware, reviewed the changes that the cloud computing industry has gone through over the last five years and shared insights into what the next five will bring. He also chronicled the challenges enterprise companies are facing as they move to the public cloud. He delved into the "Hybrid Cloud" space and explained why every CIO should consider ‘hybrid cloud' as part of their future strategy to achie...
Jul. 6, 2015 03:00 PM EDT Reads: 1,714
"Plutora provides release and testing environment capabilities to the enterprise," explained Dalibor Siroky, Director and Co-founder of Plutora, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
Jul. 6, 2015 03:00 PM EDT Reads: 1,734
DevOps tends to focus on the relationship between Dev and Ops, putting an emphasis on the ops and application infrastructure. But that’s changing with microservices architectures. In her session at DevOps Summit, Lori MacVittie, Evangelist for F5 Networks, will focus on how microservices are changing the underlying architectures needed to scale, secure and deliver applications based on highly distributed (micro) services and why that means an expansion into “the network” for DevOps.
Jul. 6, 2015 03:00 PM EDT Reads: 3,001
Jul. 6, 2015 03:00 PM EDT Reads: 384
Jul. 6, 2015 02:45 PM EDT Reads: 776
Jul. 6, 2015 02:30 PM EDT Reads: 561
Jul. 6, 2015 02:15 PM EDT Reads: 961
Jul. 6, 2015 02:15 PM EDT Reads: 1,824
Jul. 6, 2015 02:00 PM EDT Reads: 1,218
Jul. 6, 2015 02:00 PM EDT Reads: 2,078
Jul. 6, 2015 02:00 PM EDT Reads: 1,371
Jul. 6, 2015 01:45 PM EDT Reads: 2,098
Jul. 6, 2015 01:30 PM EDT Reads: 2,632
Jul. 6, 2015 01:30 PM EDT Reads: 1,483
Jul. 6, 2015 01:30 PM EDT Reads: 2,301